Neugenesis Corporation is focused on generating better biotherapeutics, cost-effectively. To this end, Neugenesis has developed technology that has substantial value in the discovery, improvement and production of complex proteins; especially heteromeric proteins. The Company's work with the filamentous fungi Neurospora crassa has resulted in significant advances in three important areas of biotechnology: recombinant protein expression, directed evolution, and combinatorial biology.
Our novel platform for protein expression (NeuBIOS™) brings a low cost/high value solution to vaccine and monoclonal antibody production. Neugenesis has generated proprietary technology for the rapid and inexpensive production of:
- Recombinant antigens and vaccines for infectious human diseases.
- Veterinary vaccines.
- High value biotherapeutics.
- Industrial enzymes.
Neugenesis is currently carrying out two client funded proof of concept programs:
- Development of seasonal and pandemic influenza vaccines for PATH, a non-profit dedicated to supplying vaccines to underdeveloped countries.
- A contract with the Defense Advanced Research Projects Agency (DARPA) to develop production technology for monoclonal antibodies and vaccines.
The Neugenesis platform offers a number of advantages:
- Basic platform produces a variety of biologics.
- Avoids entangling patent issues (Cabilly II patent).
- High production yield potential.
- Development times for new products as short as 12 weeks.
- Reduced capital requirements:
bioreactors <1000 liters. - Short fermentation time (<7 days).
- Minimal media and simplified protein recovery.
- Tailored multivalent vaccines - mix and match antigens.
- Ability to store production strains for rapid reintroduction to the manufacturing stream.
- Scalability and flexibility.
- Non-pathogenic host organisms.
- Protein refolding is rarely an issue.
- Glycosylation is more mammalian than bacterial systems.
- For influenza vaccine production:
- 5 weeks to generate a strain expressing a new variant.
- 7 weeks from cell bank to harvest of bulk product.
